COGNITIVE & NOOTROPIC RESEARCH / MATRIX
DSIP and Semax, Side by Side
How a sleep peptide and a focus peptide differ in mechanism, evidence quality, studied route, and what you do and do not yet know about each.
The short version
This page lines up DSIP and Semax on the dimensions that matter most when reading research on calm-, focus-, and sleep-oriented peptides: mechanism, evidence base, studied route of administration, regulatory standing, and the single most important caution for each. The short version: DSIP has an unresolved mechanism and inconsistent evidence, including a large non-response rate; Semax has a much better-characterized mechanism and a coherent (if mostly rodent) evidence base, plus a genuine Russian human-use history. Neither is FDA-approved for anything, and nothing here is medical advice or a recommended dose.
The comparison matrix
| Dimension | DSIP | Semax |
|---|---|---|
| Peptide class | Endogenous nonapeptide; no identified receptor, gene, or precursor after 40+ years of study | Synthetic ACTH(4-10) analog (heptapeptide) with a specific, measured brain binding site |
| Most-studied for | Sleep architecture, stress (HPA) axis, neuroendocrine secretion | Cognition, memory, mood, neuroprotection after stroke and spinal-cord injury |
| Evidence base | Small 1980s human trials plus scattered rodent/geroprotector studies; a 2006 review calls the sleep link "still unresolved" [2] | Decades of Russian rodent and some human work; recent (2025) injury-model mechanistic studies [6][7] |
| Route studied | Intravenous (clinical studies) | Intranasal |
| Regulatory status | Not approved anywhere; sold only as a research chemical | Registered prescription drug in Russia and Ukraine only; research chemical elsewhere |
| Key caution | Genuinely unknown mechanism, and roughly half of users report no effect at all | Nasal irritation, short duration, and unstudied potentiation of stimulants and antidepressants [12] |
Mechanism
The two compounds sit at opposite poles of "how well is this understood." DSIP has no identified receptor, gene, or precursor protein despite more than forty years of research — a 2006 review summarized it as a "still unresolved riddle" [2]. What limited mechanistic threads exist are indirect: a blood-brain-barrier transporter shared with the amino acid tryptophan, and a dopamine-relay effect on growth hormone. Semax, by contrast, binds a specific, reversible, calcium-dependent site in rat brain tissue with a measured dissociation constant of 2.4 nanomolar [9], and reliably raises the neurotrophins BDNF and NGF in specific brain regions within hours of dosing [8][9]. That is a genuinely different tier of mechanistic evidence, even though both remain unapproved research chemicals.
Most-studied application
DSIP's literature clusters around sleep and the stress-hormone (HPA) axis, plus a smaller and more contested body of animal longevity work [3][4][5]. Semax's literature clusters around cognition, mood, and neuroprotection — it has been studied in rodent models of stroke, spinal-cord injury, and memory tasks, with a consistent finding that it raises brain growth factors and shifts immune/vascular gene expression after injury [6][7][10]. The two rarely overlap in what they're actually tested for, which is part of why they anchor opposite ends of this desk's daily-rhythm framing.
Evidence base
This is where the two genuinely separate. DSIP's human evidence is limited to a handful of small 1980s trials and short neuroendocrine experiments, and its clearest modern positive result — a 2024 engineered fusion peptide, not native DSIP — actually underscores how much the plain molecule underperforms in comparison [1][2]. Semax's evidence base is deeper and more mechanistically specific, spanning gene-expression studies, radiolabeled pharmacokinetics, specific-binding assays, and injury-model outcomes as recent as 2025 [6][8][9][11] — but it remains overwhelmingly a rodent literature, with human use concentrated in Russian and Ukrainian clinical practice rather than Western randomized trials.
Route studied
DSIP's clinical human studies used intravenous administration [4][5], a route with no real analog in how people use it informally today. Semax's studied and clinically used route is intranasal [11], which is also how it is most commonly used outside clinical settings — meaning the studied route and the community-used route line up more closely for Semax than for DSIP.
Regulatory and approval status
Neither compound has FDA or EMA approval. Semax is a registered prescription medicine in Russia and Ukraine for conditions including ischemic stroke and cognitive impairment; DSIP has never achieved regulatory approval anywhere, even though its International Nonproprietary Name (Emideltide) exists on paper with no approved product behind it. Outside that narrow Russian/Ukrainian niche for Semax, both are handled purely as unregulated research chemicals.
Key caution
For DSIP, the defining caution is the combination of a genuinely unknown mechanism and a large, honestly reported non-response rate — a real chance of feeling nothing at all, alongside cited cautions about unpredictable timing and headache [2]. For Semax, the defining caution is different in character: a much better-understood but still incompletely characterized action on neurotrophin and opioid-peptide signaling, paired with unstudied potentiation of stimulants and antidepressants and the practical nuisance of nasal irritation and a short duration of effect [9][12]. Read together, the pattern is that better-characterized mechanism does not mean fewer open questions — just different ones.